SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia

Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer

(2019) Angela Esposito et al.   JAMA Oncology

Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma

(2019) Adel Eltantawy et al.   ANNALS OF PHARMACOTHERAPY

PI3K isoforms in cell signalling and vesicle trafficking

(2019) Benoit Bilanges et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin’s lymphoma

(2018) Thomas D. Rodgers et al.   EXPERT OPINION ON EMERGING DRUGS

Targeting the B cell receptor pathway in non-Hodgkin lymphoma

(2018) Kelly Valla et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

(2018) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the PI3K pathway in cancer: are we making headway?

(2018) Filip Janku et al.   Nature Reviews Clinical Oncology

Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study

(2018) Ian W. Flinn et al.   AMERICAN JOURNAL OF HEMATOLOGY

Non-Hodgkin lymphoma

(2018) Anna Bowzyk Al-Naeeb et al.   BMJ-British Medical Journal

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma

(2017) Benjamin L. Lampson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

(2017) Sonali M Smith et al.   Lancet Haematology

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis

(2016) Fernando Cabanillas et al.   Clinical Lymphoma Myeloma & Leukemia

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential

(2016) Jacqueline C. Barrientos   OncoTargets and Therapy

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

(2015) Carla Casulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia

(2014) J. R. Brown et al.   BLOOD

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma

(2014) I. W. Flinn et al.   BLOOD

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms

(2013) Ralph Fritsch et al.   CELL

PI3K in cancer–stroma interactions: bad in seed and ugly in soil

(2013) E Hirsch et al.   ONCOGENE

Management of indolent lymphoma: Where are we now and where are we going

(2012) Matthew A. Lunning et al.   BLOOD REVIEWS

Non-Hodgkin lymphoma

(2012) Kate R Shankland et al.   LANCET

PI3K signalling: the path to discovery and understanding

(2012) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

(2011) X. C. Badoux et al.   BLOOD

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function

(2010) Wai-Ping Fung-Leung   CELLULAR SIGNALLING

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Fine tuning the immune response with PI3K

(2009) David A. Fruman et al.   IMMUNOLOGICAL REVIEWS

High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation

(2008) J. A. Burger et al.   BLOOD

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

(2008) C Garcia-Echeverria et al.   ONCOGENE